News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Open Biosystems and Abcam plc Announce Partnership to Match Antibodies with Genetic Content

8/9/2007 8:09:22 AM

HUNTSVILLE, Ala., Aug. 8 /PRNewswire/ -- Open Biosystems, Inc. and Abcam, Plc., (AIM: ABC), announced today that they have entered into an agreement under which Open Biosystems will sell Abcam's primary antibodies alongside Open's libraries of cDNA, ORF and shRNA clones. The agreement creates the world's most extensive resource of genetic content for the analysis of gene function.


Customers will be able to use the advanced gene search tool at Open's website to query by gene symbol or accession to bring up an index of all of the matched content available to study a gene. Matched products will be shipped together within 48 hours of order receipt.

Matt Baker, Executive VP of Business Development at Open, said, "Open Biosystems continues to enhance the value of genetic content available for academic and commercial scientists. The agreement with Abcam further enables researchers to have access to a comprehensive solution for functional gene analysis expressing a gene, knocking down a gene and detecting the gene product all from one provider."

"Traditionally researchers would have to clone their own genes, custom order shRNAs or siRNAs, and search for a separate source of antibodies. Open Biosystems offers the ability to eliminate all of these steps and purchase the products together. Abcam has proven to be one of the highest quality sources for catalog antibodies, and we are excited about working with them," added Brian Pollock, CEO of Open.

Jonathan Milner, CEO of Abcam said, "We are delighted to sign this agreement with Open Biosystems. Abcam is recognized in the marketplace for the quality of our products and we are happy to provide Open Biosystems with a selection of our products for distribution alongside their comprehensive range of gene content analysis components. We are enthusiastic to be working alongside Open Biosystems, and I believe it will allow both companies to expand in this exciting part of the market.

About Open Biosystems

Open Biosystems, Inc. is a leader in gene analysis developing, manufacturing and marketing genomic and proteomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with high-quality genes for over- expression analysis, RNAi for gene knockdown and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, visit

About Abcam, Plc.

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of approximately 35,000 products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs 130 staff in its three operating companies.

Photo: Biosystems, Inc.

CONTACT: Matt Baker of Open Biosystems Inc., +1-256-319-1422,

Read at

comments powered by Disqus